I stand corrected. The original release could be clearer.
Irrespective, we have a double blind, randomized study run and reviewed by independent professional bodies, that stands head and shoulders above the crap being released by companies. Its very frustrating watching these unprofressional releases by vaccine and anti-viral companies on tenuous phase 2 data sending stocks higher (though I suppose MSB did similar in April), but I will have to exercise patience until the 1st 90 patient window, when hopefully efficacy stops the trials on ethical reasons and the placebo group are put onto REM-L on emergency access protocols which the company already has.
Countdown to Interim Analysis, page-95
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |